SG11202107238UA - Method of detecting a neurodegenerative disease - Google Patents

Method of detecting a neurodegenerative disease

Info

Publication number
SG11202107238UA
SG11202107238UA SG11202107238UA SG11202107238UA SG11202107238UA SG 11202107238U A SG11202107238U A SG 11202107238UA SG 11202107238U A SG11202107238U A SG 11202107238UA SG 11202107238U A SG11202107238U A SG 11202107238UA SG 11202107238U A SG11202107238U A SG 11202107238UA
Authority
SG
Singapore
Prior art keywords
detecting
neurodegenerative disease
neurodegenerative
disease
Prior art date
Application number
SG11202107238UA
Inventor
Huilin Shao
Zhi Jun Carine Lim
Yan Zhang
Li-Hsian Christopher Chen
Tze Ping LOH
Original Assignee
Nat Univ Singapore
Nat Univ Hospital Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Singapore, Nat Univ Hospital Singapore Pte Ltd filed Critical Nat Univ Singapore
Publication of SG11202107238UA publication Critical patent/SG11202107238UA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/55Specular reflectivity
    • G01N21/552Attenuated total reflection
    • G01N21/553Attenuated total reflection and using surface plasmons
    • G01N21/554Attenuated total reflection and using surface plasmons detecting the surface plasmon resonance of nanostructured metals, e.g. localised surface plasmon resonance
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/553Metal or metal coated
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/285Demyelinating diseases; Multipel sclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202107238UA 2019-01-31 2020-01-30 Method of detecting a neurodegenerative disease SG11202107238UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201900940Y 2019-01-31
PCT/IB2020/050764 WO2020157705A1 (en) 2019-01-31 2020-01-30 Method of detecting a neurodegenerative disease

Publications (1)

Publication Number Publication Date
SG11202107238UA true SG11202107238UA (en) 2021-07-29

Family

ID=71841387

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107238UA SG11202107238UA (en) 2019-01-31 2020-01-30 Method of detecting a neurodegenerative disease

Country Status (6)

Country Link
US (1) US20220397580A1 (en)
EP (1) EP3918327A4 (en)
JP (1) JP2022519583A (en)
CN (1) CN113614531A (en)
SG (1) SG11202107238UA (en)
WO (1) WO2020157705A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023080102A1 (en) * 2021-11-04 2023-05-11 凸版印刷株式会社 METHOD FOR DETECTING AMYLOID-β BOUND TO BRAIN-NEURONAL-CELL-DERIVED EXOSOME IN BLOOD, KIT FOR DETECTION OF AMYLOID-β BOUND TO BRAIN-NEURONAL-CELL-DERIVED EXOSOME IN BLOOD, AND METHOD FOR EVALUATING ACCUMULATION LEVEL OF AMYLOID-β IN BRAIN
WO2023232108A1 (en) * 2022-06-02 2023-12-07 浙江大学医学院附属第一医院 Method, system, composition, and kit for diagnosing and identifying non-alzheimer's disease cognitive disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2963791B1 (en) * 2010-08-11 2012-09-21 Assist Publ Hopitaux De Paris METHOD OF DIAGNOSING NEURODEGENERATIVE DISEASES
JP6074746B2 (en) * 2011-10-14 2017-02-08 国立大学法人北海道大学 Drug for amyloid β-related diseases and screening thereof
CA2926092A1 (en) * 2013-10-24 2015-04-30 Nanosomix, Inc. Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
CN106062559B (en) * 2014-06-27 2018-12-14 北京新源长青生物科技有限公司 Method for being enriched with the excretion body in the source CNS
WO2016201323A1 (en) * 2015-06-10 2016-12-15 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
WO2017087467A1 (en) * 2015-11-20 2017-05-26 Exosome Sciences, Inc. Exosomal tau as a biomarker for brain disorders
US11243215B2 (en) * 2016-01-14 2022-02-08 The Regents Of The University Of California 3D-exoquant method for the analysis of surface molecules and quantification of tissue-specific exosomes in biological fluids
EP3452828A4 (en) * 2016-05-06 2019-12-04 Nanosomix Inc. Synaptic protein biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders
KR102048987B1 (en) * 2017-02-22 2019-11-27 한국과학기술연구원 Information providing method for identification of neurodegenerative disorder
WO2018218090A1 (en) * 2017-05-24 2018-11-29 Nanosomix, Inc. Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders

Also Published As

Publication number Publication date
WO2020157705A1 (en) 2020-08-06
CN113614531A (en) 2021-11-05
JP2022519583A (en) 2022-03-24
EP3918327A1 (en) 2021-12-08
EP3918327A4 (en) 2022-11-23
US20220397580A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
EP3781458C0 (en) Method for determining a turning radius
IL243386A0 (en) A method for extracting latent context patterns from sensors
GB201915444D0 (en) Method of using a blockchain
GB201805954D0 (en) A method
GB201804627D0 (en) A method of communicating
GB201809450D0 (en) Method for detecting a tandem repeat
SG11202107238UA (en) Method of detecting a neurodegenerative disease
IL291367A (en) Method for determining a field-of-view setting
GB201902908D0 (en) Method of using a blockchain
GB201611652D0 (en) Method of detecting a condition
SG11202006997SA (en) A method of determining a risk of cancer
IL283892A (en) A method for determining a chemotypic profile
IL280423A (en) A method for identifying intermediates
IL276898A (en) A method of detecting magea4
SG11202105280QA (en) Method of identifying a structure
SG11202105311VA (en) Method of identifying a structure
EP3728280C0 (en) Method for improving the oral bioavailability of a drug
GB201807651D0 (en) A method of detection
GB201813722D0 (en) A method
ZA202006375B (en) A method of carbonizate purification
IL281333A (en) Method of derisking a clinical trial
EP3647943C0 (en) Method for determining at least one characteristic of at least a change
PL3316066T3 (en) Method for determining at least a part of a border
GB201813730D0 (en) A method
GB201809530D0 (en) A method